Hereditary angioedema is caused by abnormalities in C1 inhibitor levels or functionality. Past treatments for acute attacks included IV fluids and pain/nausea medications, while long-term prophylaxis included anabolic androgens or antifibrinolytics. Newly approved treatments in the US include plasma-derived C1INH concentrates like Berinert and Cinryze, which have been shown in clinical trials to significantly shorten time to relief of symptoms from acute attacks. Cinryze has also been approved for prophylaxis as it significantly reduced the rate of attacks compared to placebo in a clinical trial. Additionally, the plasma kallikrein inhibitor ecallantide was approved for
Hereditary angioedema (HAE) is caused by C1 inhibitor deficiency or dysfunction. There are three main types: HAE type I and II involve C1INH mutations, while HAE type III has normal C1INH levels. Symptoms include non-pruritic swelling of the skin or mucosa. Abdominal or laryngeal attacks can be life-threatening. Diagnosis involves evaluating C1INH antigenic and functional levels. Treatment focuses on preventing attacks or treating acute episodes. Acquired angioedema has similar symptoms but later onset and is sometimes associated with lymphoproliferative disorders.
Rheumatology MCQs Practice questions with explanationDr. Almas A
Topic: Rheumatology
Exam type: MCQs Practice questions
Q. A 26-year-old female presented to ER with dry cough and shortness of breath and often complains of chest pain. Chest x-ray shows bilateral hilar lymphadenopathy. Which of the following will indicate that the patient suffers from sarcoidosis?
Q: A 50-year-old female presents to ER with dyspnea on exertion and orthopnea, red painful eyes. She complains of chronic dull pain in the gluteal region for the last 5 years and stiffness in the lower back that wakes her up in the morning. X-ray spine reveals squaring of vertebrae with bone spur formation. On MRI sacroiliitis is seen. Which of the following is the most likely diagnosis?
Q: A 60-year-old female presents in OPD with knee joint stiffness in the morning and increases with activity and decreases on rest. She also complains about a crackling noise on joint movement. X-ray shows narrowing of the joint space and osteophytes. Which of the following treatments is recommended in this patient?
Q: A 70-year-old female presented to ER with swelling of knee joint and severe pain. Arthrocentesis revealed rhomboid-shaped crystals that stained deeply blue with H&E stain, and show weak positive birefringence on light microscopy. X-ray reveals chondrocalcinosis. Which of the following statements is true?
Q: A 40-year-old female comes to OPD with dry eyes and dyspareunia for the last 6 months. She also complains of cough and fatigue with joint pains. On examination, her parotid gland was enlarged and laboratory tests revealed anti-Ro antibodies are positive. Which of the following tests is recommended to this patient?
granulomatosis with polyangiitis (Wegener’s granulomatosis) Ameen Rageh
This document discusses Wegener's granulomatosis (now called granulomatosis with polyangiitis or GPA), a rare multisystem autoimmune disease characterized by necrotizing vasculitis and granulomatous inflammation that commonly involves the respiratory tract and kidneys. Key points include:
- GPA is associated with circulating ANCA antibodies and causes necrotizing inflammation of small to medium vessels.
- Common clinical manifestations involve the upper respiratory tract, lungs, and kidneys. Chest imaging often shows nodules/masses, cavities, ground glass opacities and consolidations.
- Diagnosis is based on clinical features, labs including positive ANCA, and biopsy
This document discusses monoclonal antibody treatments for asthma, focusing on omalizumab. It defines asthma and describes its symptoms and classifications. It explains the role of IgE in asthma and the mechanism of action of omalizumab, which inhibits IgE binding to prevent mast cell degranulation. It covers the pharmacokinetics, dosing, safety, and indications of omalizumab. It also briefly mentions other monoclonal antibodies in development for treating asthma, such as mepolizumab, anti-TNF antibodies, and antibodies targeting IL-13, TIM-1, and tissue kallikrein 1.
Hereditary angioedema (HAE) is a rare disease caused by C1 inhibitor deficiency and characterized by recurrent episodes of non-pruritic swelling in the skin, gastrointestinal tract, and airways. The disease has an autosomal dominant pattern of inheritance and is caused by mutations in the C1 inhibitor gene. Diagnosis involves evaluating family history, symptoms of recurrent non-pitting edema, and laboratory tests showing low C4 and C1 inhibitor levels. Proper diagnosis is important to distinguish it from other causes of angioedema and manage attacks.
Eosinophilic granulomatosis with polyangitisMarwa Besar
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic vasculitis characterized by eosinophilia, asthma, and small vessel vasculitis. It can affect multiple organ systems including the lungs, heart, skin, gastrointestinal tract, and nerves. Diagnosis is based on clinical criteria of asthma, eosinophilia, vasculitic manifestations, and tissue biopsy showing eosinophilic inflammation. Treatment involves glucocorticoids and immunosuppressants. Prognosis is generally good but relapses are common if treatment is stopped early.
This document discusses systemic juvenile idiopathic arthritis (S-JIA), including its clinical presentation, course, treatment and pulmonary complications. S-JIA is characterized by quotidian fever, evanescent rash, arthritis, lymphadenopathy, hepatosplenomegaly and serositis. It can follow a variable course from monophasic to persistent. Complications include macrophage activation syndrome (MAS), growth failure, joint damage and amyloidosis. New targeted biologics like anti-IL-1 and anti-IL-6 agents are the current recommended treatment approaches. The document also notes several reported cases of pulmonary hypertension and interstitial lung disease in S-JIA patients and questions what disease
This document provides information on autoimmune hepatitis, including:
- It is a chronic hepatitis of unknown etiology that can progress to cirrhosis. It is characterized by the presence of autoimmune antibodies and evidence of hepatitis.
- The two main types are type 1, associated with ANA/SMA positivity, and type 2, associated with LKM1 positivity.
- Treatment involves immunosuppressive drugs like prednisone, either alone or in combination with azathioprine. The goal is to induce and maintain remission.
- Remission is defined as resolution of symptoms and normalization of liver tests and histology. Treatment is then tapered slowly to maintain remission.
Hereditary angioedema (HAE) is caused by C1 inhibitor deficiency or dysfunction. There are three main types: HAE type I and II involve C1INH mutations, while HAE type III has normal C1INH levels. Symptoms include non-pruritic swelling of the skin or mucosa. Abdominal or laryngeal attacks can be life-threatening. Diagnosis involves evaluating C1INH antigenic and functional levels. Treatment focuses on preventing attacks or treating acute episodes. Acquired angioedema has similar symptoms but later onset and is sometimes associated with lymphoproliferative disorders.
Rheumatology MCQs Practice questions with explanationDr. Almas A
Topic: Rheumatology
Exam type: MCQs Practice questions
Q. A 26-year-old female presented to ER with dry cough and shortness of breath and often complains of chest pain. Chest x-ray shows bilateral hilar lymphadenopathy. Which of the following will indicate that the patient suffers from sarcoidosis?
Q: A 50-year-old female presents to ER with dyspnea on exertion and orthopnea, red painful eyes. She complains of chronic dull pain in the gluteal region for the last 5 years and stiffness in the lower back that wakes her up in the morning. X-ray spine reveals squaring of vertebrae with bone spur formation. On MRI sacroiliitis is seen. Which of the following is the most likely diagnosis?
Q: A 60-year-old female presents in OPD with knee joint stiffness in the morning and increases with activity and decreases on rest. She also complains about a crackling noise on joint movement. X-ray shows narrowing of the joint space and osteophytes. Which of the following treatments is recommended in this patient?
Q: A 70-year-old female presented to ER with swelling of knee joint and severe pain. Arthrocentesis revealed rhomboid-shaped crystals that stained deeply blue with H&E stain, and show weak positive birefringence on light microscopy. X-ray reveals chondrocalcinosis. Which of the following statements is true?
Q: A 40-year-old female comes to OPD with dry eyes and dyspareunia for the last 6 months. She also complains of cough and fatigue with joint pains. On examination, her parotid gland was enlarged and laboratory tests revealed anti-Ro antibodies are positive. Which of the following tests is recommended to this patient?
granulomatosis with polyangiitis (Wegener’s granulomatosis) Ameen Rageh
This document discusses Wegener's granulomatosis (now called granulomatosis with polyangiitis or GPA), a rare multisystem autoimmune disease characterized by necrotizing vasculitis and granulomatous inflammation that commonly involves the respiratory tract and kidneys. Key points include:
- GPA is associated with circulating ANCA antibodies and causes necrotizing inflammation of small to medium vessels.
- Common clinical manifestations involve the upper respiratory tract, lungs, and kidneys. Chest imaging often shows nodules/masses, cavities, ground glass opacities and consolidations.
- Diagnosis is based on clinical features, labs including positive ANCA, and biopsy
This document discusses monoclonal antibody treatments for asthma, focusing on omalizumab. It defines asthma and describes its symptoms and classifications. It explains the role of IgE in asthma and the mechanism of action of omalizumab, which inhibits IgE binding to prevent mast cell degranulation. It covers the pharmacokinetics, dosing, safety, and indications of omalizumab. It also briefly mentions other monoclonal antibodies in development for treating asthma, such as mepolizumab, anti-TNF antibodies, and antibodies targeting IL-13, TIM-1, and tissue kallikrein 1.
Hereditary angioedema (HAE) is a rare disease caused by C1 inhibitor deficiency and characterized by recurrent episodes of non-pruritic swelling in the skin, gastrointestinal tract, and airways. The disease has an autosomal dominant pattern of inheritance and is caused by mutations in the C1 inhibitor gene. Diagnosis involves evaluating family history, symptoms of recurrent non-pitting edema, and laboratory tests showing low C4 and C1 inhibitor levels. Proper diagnosis is important to distinguish it from other causes of angioedema and manage attacks.
Eosinophilic granulomatosis with polyangitisMarwa Besar
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic vasculitis characterized by eosinophilia, asthma, and small vessel vasculitis. It can affect multiple organ systems including the lungs, heart, skin, gastrointestinal tract, and nerves. Diagnosis is based on clinical criteria of asthma, eosinophilia, vasculitic manifestations, and tissue biopsy showing eosinophilic inflammation. Treatment involves glucocorticoids and immunosuppressants. Prognosis is generally good but relapses are common if treatment is stopped early.
This document discusses systemic juvenile idiopathic arthritis (S-JIA), including its clinical presentation, course, treatment and pulmonary complications. S-JIA is characterized by quotidian fever, evanescent rash, arthritis, lymphadenopathy, hepatosplenomegaly and serositis. It can follow a variable course from monophasic to persistent. Complications include macrophage activation syndrome (MAS), growth failure, joint damage and amyloidosis. New targeted biologics like anti-IL-1 and anti-IL-6 agents are the current recommended treatment approaches. The document also notes several reported cases of pulmonary hypertension and interstitial lung disease in S-JIA patients and questions what disease
This document provides information on autoimmune hepatitis, including:
- It is a chronic hepatitis of unknown etiology that can progress to cirrhosis. It is characterized by the presence of autoimmune antibodies and evidence of hepatitis.
- The two main types are type 1, associated with ANA/SMA positivity, and type 2, associated with LKM1 positivity.
- Treatment involves immunosuppressive drugs like prednisone, either alone or in combination with azathioprine. The goal is to induce and maintain remission.
- Remission is defined as resolution of symptoms and normalization of liver tests and histology. Treatment is then tapered slowly to maintain remission.
Procalcitonin is a biomarker that is more specific than others for bacterial infection. It rises rapidly within 6 hours of an insult and declines quickly with treatment. It is not impacted by anti-inflammatory states and correlates well with illness severity. Procalcitonin levels can be used to differentiate between bacterial and viral lung infections, diagnose and monitor sepsis and septic shock, monitor antibiotic treatment response, and diagnose secondary infections. Reference values are provided and recommendations include measuring PCT at initiation of suspected conditions and repeating every 2-3 days to guide antibiotic use along with culture and clinical data.
i. Subacute sclerosing panencephalitis (SSPE) is a rare progressive neurological disorder caused by persistent measles virus infection of the brain. It presents with personality changes, myoclonus, rigidity and progressive deterioration.
ii. Pathologically, it is characterized by neuronal inclusion bodies containing measles virus antigens. MRI may show non-specific white matter changes while EEG typically shows periodic complexes correlated with myoclonus. There is no cure and treatment is supportive only.
iii. Risk factors include measles exposure before 2 years of age. Prognosis is poor with most patients dying within 3 years, though rare spontaneous remissions occur in 5-6% of
Hyper IgM Syndrome is characterized by immunodeficiency with elevated serum IgM and low or absent other immunoglobulins due to a defect in class switching recombination. The most common form is X-linked Hyper IgM Syndrome caused by mutations in the CD40 ligand gene, affecting approximately 1 in 1,000,000 males. Clinical manifestations include recurrent respiratory and gastrointestinal infections. Treatment involves hematopoietic stem cell transplantation which is curative but has better outcomes when performed at a younger age before organ damage develops.
This document provides an outline and overview of allergic rhinitis. It begins with definitions and classifications of allergic rhinitis. It then discusses the epidemiology and prevalence globally. The pathophysiology and mechanisms are explained, including sensitization, IgE production, and response to allergens. Various risk factors are reviewed such as genetics, allergens, pollution, and socioeconomic status. Protective factors like breastfeeding are also mentioned. Evaluation, associated conditions, and management strategies are outlined but not described in detail.
Paraneoplastic syndromes are diseases or symptoms caused by cancer but not by direct local effects of tumors. They are mediated through cross-reacting antibodies, physiologically active factors, or metabolic pathway interference. Syndromes are classified as endocrine, neurological, mucocutaneous, hematological, or other. Common endocrine syndromes include Cushing's syndrome, SIADH, hypoglycemia, and hypercalcemia. Neurological syndromes are often antibody-mediated and include Lambert-Eaton myasthenic syndrome and paraneoplastic cerebellar degeneration. Dermatological manifestations incorporate lesions like acanthosis nigricans. Treatment focuses on managing symptoms and removing the underlying tumor.
1. The document discusses various types of primary vasculitis classified by vessel size, including giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa, Kawasaki disease, eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), and Henoch-Schönlein purpura.
2. It provides details on clinical presentations, investigations, treatments, and pathogenic mechanisms of these conditions.
3. Granulomatosis with polyangiitis is characterized by necrotizing granulomatous vasculitis of the upper and lower airways
This document defines and outlines Churg-Strauss Syndrome (CSS), a rare eosinophilic vasculitis disease. It provides details on the epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of CSS. CSS is characterized by eosinophil-rich inflammation involving small to medium blood vessels and is associated with asthma, allergies, and eosinophilia. Treatment involves high doses of corticosteroids, with immunosuppressants used for resistant cases. Prognosis is generally better than other vasculitis diseases but mortality can occur from cardiac or neurological involvement.
This document provides an overview of chronic spontaneous urticaria (CSU), including its epidemiology, pathophysiology, clinical presentation, investigations, and management. It discusses the diagnosis and classification of urticaria and focuses on the diagnosis and investigation of CSU. Routine diagnostic measures for CSU include CBC, ESR or CRP, and eliminating possible causes such as medications or foods. Extended diagnostic testing may include allergy testing, infections screening, autoantibody testing such as the autologous serum skin test, and screening for underlying conditions. The gold standard treatment for CSU is non-sedating H1 antihistamines as monotherapy or in increased doses. Refractory cases may require the addition
Approach to a patient with fever of unknown origin sunil kumar daha
Please find the power point on Approach to a patient with fever of unknown origin . I tried to present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
Hypersensitivity pneumonitis (HP) is an interstitial lung disease caused by repeated inhalation and sensitization to various antigens. It affects the lung interstitium and has variable clinical presentations. Common causative agents include avian and microbial antigens. The immunopathogenesis involves both humoral and cellular immune responses. HP is classified as acute, subacute, or chronic based on clinical manifestations. Diagnosis relies on a history of antigen exposure, precipitating antibodies, clinical features, imaging, and pathology. Chest radiography and HRCT are important diagnostic tools, with HRCT showing findings like nodules, ground glass opacity, and fibrosis that vary depending on the disease stage.
This document summarizes the treatment of granulomatosis with polyangiitis (GPA), formerly known as Wegener's granulomatosis. It describes initial immunosuppressive therapy including glucocorticoids combined with cyclophosphamide or rituximab for moderate to severe disease. Maintenance immunosuppressive therapy options include methotrexate, azathioprine and low dose glucocorticoids, typically continued for 12-18 months after remission is achieved. Prophylactic treatments and management of organ system involvement are also outlined.
Henoch–Schönlein purpura (HSP) is the most common vasculitis of childhood that presents with a tetrad of purpura, arthritis/arthralgia, abdominal pain, and renal involvement. It is characterized by IgA-containing immune complexes depositing in small vessels, skin, GI tract, joints, and kidneys. The diagnosis is based on purpura with lower limb predominance and at least one of the other criteria. Imaging and labs help assess organ involvement while biopsy confirms the diagnosis.
This document summarizes key aspects of immunotherapy. It discusses the history and mechanisms of immunotherapy, indications for its use, types of allergen extracts, administration schedules, safety considerations, and special populations. Specifically, it notes that immunotherapy involves administering allergens to desensitize patients, works by altering the immune response, and is effective for respiratory allergies and insect venom. Safety monitoring and premedication can reduce risks of local and systemic reactions.
The document discusses properties, modes of action, indications, and administration of intravenous immunoglobulin (IVIg). It provides details on the plasma fractionation process used to produce IVIg and notes that IVIg contains 98% IgG and traces of other immunoglobulins. The document also examines IVIg's mechanisms of action, FDA-approved uses, evidence for off-label uses, and potential adverse effects.
Reye syndrome is characterized by acute noninflammatory encephalopathy and fatty degenerative liver failure. It primarily affects the brain and liver, and can affect all organs. It has a biphasic course beginning with a viral illness that resolves, followed by abrupt onset of vomiting and neurologic impairment. The cause is unknown but aspirin use during a viral illness increases risk significantly. Diagnosis requires evidence of encephalopathy, hepatopathy, and no other reasonable explanations. Prognosis depends on stage - later stages involve deep coma and have high mortality.
Urticaria, Angioedema, and Anaphylaxis.pptxJwan AlSofi
This document provides an overview of urticaria, angioedema, and anaphylaxis. It defines the conditions, describes their pathophysiology as being related to mast cell degranulation and mediator release, and classifies them as acute, chronic, physical, or hereditary. Epidemiology, clinical manifestations, diagnostic approach, differential diagnosis, treatment involving antihistamines and epinephrine, and prevention are discussed. Anaphylaxis is emphasized as a medical emergency requiring immediate epinephrine injection and supportive care.
To download my ANIMATED presenation VISIT
https://www.dropbox.com/s/5rfb35jcq45uexa/ANIAngioedema.pptx?m
To watch my ANIMATED vedio presentation VISIT
www.youtube.com/watch?v=hlqNGUGphuk
Thank you
Procalcitonin is a biomarker that is more specific than others for bacterial infection. It rises rapidly within 6 hours of an insult and declines quickly with treatment. It is not impacted by anti-inflammatory states and correlates well with illness severity. Procalcitonin levels can be used to differentiate between bacterial and viral lung infections, diagnose and monitor sepsis and septic shock, monitor antibiotic treatment response, and diagnose secondary infections. Reference values are provided and recommendations include measuring PCT at initiation of suspected conditions and repeating every 2-3 days to guide antibiotic use along with culture and clinical data.
i. Subacute sclerosing panencephalitis (SSPE) is a rare progressive neurological disorder caused by persistent measles virus infection of the brain. It presents with personality changes, myoclonus, rigidity and progressive deterioration.
ii. Pathologically, it is characterized by neuronal inclusion bodies containing measles virus antigens. MRI may show non-specific white matter changes while EEG typically shows periodic complexes correlated with myoclonus. There is no cure and treatment is supportive only.
iii. Risk factors include measles exposure before 2 years of age. Prognosis is poor with most patients dying within 3 years, though rare spontaneous remissions occur in 5-6% of
Hyper IgM Syndrome is characterized by immunodeficiency with elevated serum IgM and low or absent other immunoglobulins due to a defect in class switching recombination. The most common form is X-linked Hyper IgM Syndrome caused by mutations in the CD40 ligand gene, affecting approximately 1 in 1,000,000 males. Clinical manifestations include recurrent respiratory and gastrointestinal infections. Treatment involves hematopoietic stem cell transplantation which is curative but has better outcomes when performed at a younger age before organ damage develops.
This document provides an outline and overview of allergic rhinitis. It begins with definitions and classifications of allergic rhinitis. It then discusses the epidemiology and prevalence globally. The pathophysiology and mechanisms are explained, including sensitization, IgE production, and response to allergens. Various risk factors are reviewed such as genetics, allergens, pollution, and socioeconomic status. Protective factors like breastfeeding are also mentioned. Evaluation, associated conditions, and management strategies are outlined but not described in detail.
Paraneoplastic syndromes are diseases or symptoms caused by cancer but not by direct local effects of tumors. They are mediated through cross-reacting antibodies, physiologically active factors, or metabolic pathway interference. Syndromes are classified as endocrine, neurological, mucocutaneous, hematological, or other. Common endocrine syndromes include Cushing's syndrome, SIADH, hypoglycemia, and hypercalcemia. Neurological syndromes are often antibody-mediated and include Lambert-Eaton myasthenic syndrome and paraneoplastic cerebellar degeneration. Dermatological manifestations incorporate lesions like acanthosis nigricans. Treatment focuses on managing symptoms and removing the underlying tumor.
1. The document discusses various types of primary vasculitis classified by vessel size, including giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa, Kawasaki disease, eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), and Henoch-Schönlein purpura.
2. It provides details on clinical presentations, investigations, treatments, and pathogenic mechanisms of these conditions.
3. Granulomatosis with polyangiitis is characterized by necrotizing granulomatous vasculitis of the upper and lower airways
This document defines and outlines Churg-Strauss Syndrome (CSS), a rare eosinophilic vasculitis disease. It provides details on the epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of CSS. CSS is characterized by eosinophil-rich inflammation involving small to medium blood vessels and is associated with asthma, allergies, and eosinophilia. Treatment involves high doses of corticosteroids, with immunosuppressants used for resistant cases. Prognosis is generally better than other vasculitis diseases but mortality can occur from cardiac or neurological involvement.
This document provides an overview of chronic spontaneous urticaria (CSU), including its epidemiology, pathophysiology, clinical presentation, investigations, and management. It discusses the diagnosis and classification of urticaria and focuses on the diagnosis and investigation of CSU. Routine diagnostic measures for CSU include CBC, ESR or CRP, and eliminating possible causes such as medications or foods. Extended diagnostic testing may include allergy testing, infections screening, autoantibody testing such as the autologous serum skin test, and screening for underlying conditions. The gold standard treatment for CSU is non-sedating H1 antihistamines as monotherapy or in increased doses. Refractory cases may require the addition
Approach to a patient with fever of unknown origin sunil kumar daha
Please find the power point on Approach to a patient with fever of unknown origin . I tried to present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
Hypersensitivity pneumonitis (HP) is an interstitial lung disease caused by repeated inhalation and sensitization to various antigens. It affects the lung interstitium and has variable clinical presentations. Common causative agents include avian and microbial antigens. The immunopathogenesis involves both humoral and cellular immune responses. HP is classified as acute, subacute, or chronic based on clinical manifestations. Diagnosis relies on a history of antigen exposure, precipitating antibodies, clinical features, imaging, and pathology. Chest radiography and HRCT are important diagnostic tools, with HRCT showing findings like nodules, ground glass opacity, and fibrosis that vary depending on the disease stage.
This document summarizes the treatment of granulomatosis with polyangiitis (GPA), formerly known as Wegener's granulomatosis. It describes initial immunosuppressive therapy including glucocorticoids combined with cyclophosphamide or rituximab for moderate to severe disease. Maintenance immunosuppressive therapy options include methotrexate, azathioprine and low dose glucocorticoids, typically continued for 12-18 months after remission is achieved. Prophylactic treatments and management of organ system involvement are also outlined.
Henoch–Schönlein purpura (HSP) is the most common vasculitis of childhood that presents with a tetrad of purpura, arthritis/arthralgia, abdominal pain, and renal involvement. It is characterized by IgA-containing immune complexes depositing in small vessels, skin, GI tract, joints, and kidneys. The diagnosis is based on purpura with lower limb predominance and at least one of the other criteria. Imaging and labs help assess organ involvement while biopsy confirms the diagnosis.
This document summarizes key aspects of immunotherapy. It discusses the history and mechanisms of immunotherapy, indications for its use, types of allergen extracts, administration schedules, safety considerations, and special populations. Specifically, it notes that immunotherapy involves administering allergens to desensitize patients, works by altering the immune response, and is effective for respiratory allergies and insect venom. Safety monitoring and premedication can reduce risks of local and systemic reactions.
The document discusses properties, modes of action, indications, and administration of intravenous immunoglobulin (IVIg). It provides details on the plasma fractionation process used to produce IVIg and notes that IVIg contains 98% IgG and traces of other immunoglobulins. The document also examines IVIg's mechanisms of action, FDA-approved uses, evidence for off-label uses, and potential adverse effects.
Reye syndrome is characterized by acute noninflammatory encephalopathy and fatty degenerative liver failure. It primarily affects the brain and liver, and can affect all organs. It has a biphasic course beginning with a viral illness that resolves, followed by abrupt onset of vomiting and neurologic impairment. The cause is unknown but aspirin use during a viral illness increases risk significantly. Diagnosis requires evidence of encephalopathy, hepatopathy, and no other reasonable explanations. Prognosis depends on stage - later stages involve deep coma and have high mortality.
Urticaria, Angioedema, and Anaphylaxis.pptxJwan AlSofi
This document provides an overview of urticaria, angioedema, and anaphylaxis. It defines the conditions, describes their pathophysiology as being related to mast cell degranulation and mediator release, and classifies them as acute, chronic, physical, or hereditary. Epidemiology, clinical manifestations, diagnostic approach, differential diagnosis, treatment involving antihistamines and epinephrine, and prevention are discussed. Anaphylaxis is emphasized as a medical emergency requiring immediate epinephrine injection and supportive care.
To download my ANIMATED presenation VISIT
https://www.dropbox.com/s/5rfb35jcq45uexa/ANIAngioedema.pptx?m
To watch my ANIMATED vedio presentation VISIT
www.youtube.com/watch?v=hlqNGUGphuk
Thank you
El documento proporciona una clasificación de la urticaria y el angioedema, incluido el angioedema mediado por bradicinina como el angioedema hereditario por déficit de C1 inhibidor. Describe la epidemiología, patogenia, manifestaciones clínicas, factores desencadenantes y tratamiento del angioedema hereditario por déficit de C1 inhibidor.
This document discusses the use of immunology tests in clinical practice and provides 5 case studies with multiple choice questions. It reviews tests for immunoglobulins, complement, acute antibodies, cryoglobulins, and anti-nuclear antibodies. The case studies cover conditions like hereditary angioedema, Wegener's granulomatosis, cryoglobulinemia, lupus, and common variable immune deficiency. The document emphasizes using immunology lab tests appropriately to diagnose immune-mediated diseases based on clinical presentations and symptoms.
El documento proporciona información sobre la clasificación y el tipo de angioedema mediado por bradicinina. Explica que el angioedema hereditario por déficit de C1 inhibidor es el tipo más común, el cual puede ser hereditario o adquirido. También describe brevemente la molécula de C1 inhibidor y sus funciones de inhibición en los sistemas del complemento, cininas, fibrinolisis y coagulación.
El documento describe un caso de angioedema hereditario en un niño de 16 años. Este padecimiento se caracteriza por episodios recurrentes de edema en la piel y mucosas, como labios, ojos y lengua, que duran entre 12 a 48 horas. El diagnóstico se confirma con niveles bajos de C1-INH en sangre. El tratamiento busca prevenir los episodios de edema, especialmente en vías respiratorias, mediante profilaxis a largo plazo con fármacos como danazol.
El angioedema hereditario es un trastorno genético raro caracterizado por episodios espontáneos e hinchazón de la piel, vías respiratorias u órganos internos debido a un déficit del inhibidor C1. Se hereda de forma autosómica dominante y se clasifica en tres tipos dependiendo de la causa del déficit de inhibidor C1. No existe tratamiento curativo pero los ataques agudos y prevención a largo plazo se tratan con concentrados de inhibidor C1, andrógenos u otros fármacos.
El angioedema hereditario es un edema indoloro no pruriginoso causado por una disminución de los niveles de C1-inhibidor, lo que provoca una activación descontrolada del complemento y la producción de sustancias que causan vasodilatación y aumento de la permeabilidad vascular. Puede afectar cualquier parte del cuerpo, incluida la laringe, y provocar la muerte. El tratamiento de elección para los ataques agudos es la administración de concentrado de C1-inhibidor, mientras que la profilaxis a larg
Este documento presenta el caso clínico de un paciente de 58 años que ha tenido episodios recurrentes de angioedema durante varios meses. Se detallan sus antecedentes médicos relevantes y los resultados de exámenes realizados. Adicionalmente, incluye información sobre el angioedema hereditario, su clasificación, tratamiento y factores desencadenantes.
Angioedema is localized, transient edema of the deeper layers of the dermis or mucosa caused by extravasation of plasma from capillaries and venules. It can be classified as acute or recurrent. C1 inhibitor deficiency, whether hereditary or acquired, is a major cause of angioedema. Hereditary angioedema is caused by C1 inhibitor gene mutations and results in deficient or dysfunctional C1 inhibitor. Acquired angioedema is associated with lymphoproliferative disorders or autoantibodies against C1 inhibitor. Episodes involve swelling of the skin, gastrointestinal tract or airways. Treatment involves prevention of attacks with attenuated androgens or antifibrinol
El angioedema hereditario es una enfermedad genética poco común causada por mutaciones en el gen del inhibidor C1 que provocan episodios recurrentes de angioedema. Existen tres tipos clasificados según los niveles y función del inhibidor C1. El tratamiento incluye medidas generales, reemplazo de volumen, analgésicos, concentrados del inhibidor C1 y nuevos fármacos como ecallantide e icatibant para episodios agudos, y andrógenos atenuados o antifibrinolíticos para profilaxis.
The complement system is a protective cascading system composed of 25 proteins that can be activated via the classical and alternative pathways, culminating in phagocytosis, lysis, and inflammation. It is present in normal sera and composed of complex protein networks. The classical pathway involves 9 proteins and the alternative pathway involves 13 proteins. Complement activation results in opsonization to enhance phagocytosis, attraction of phagocytes, lysis of bacteria and infected cells, and clearance of immune complexes and apoptotic cells. Deficiencies in specific complement components can increase susceptibility to certain infections due to impaired opsonization or membrane attack functions.
Angioedema is rapid swelling of subcutaneous tissues caused by increased vascular permeability. There are four main types: allergic angioedema caused by allergens, drug-induced non-allergic reactions, idiopathic angioedema of unknown cause, and hereditary angioedema (HAE) caused by C1 inhibitor deficiency. HAE is treated with C1 inhibitor concentrate, icatibant, or ecallantide while other types may be treated with antihistamines, steroids, and epinephrine if anaphylaxis is possible. Early airway management is important as angioedema can affect the tongue, larynx, and uvula and potentially cause
The complement system is an important part of the innate immune system that activates through three pathways - classical, lectin, and alternative. Activation leads to the formation of C3 and C5 convertases that generate inflammatory molecules like C3a and C5a, and opsonins like C3b that promote phagocytosis. It ultimately forms the membrane attack complex that lyses target cells. Complement is tightly regulated to prevent damage to host cells and excessive inflammation. Deficiencies in complement components can increase risk of certain infections.
The complement system is a group of proteins in the blood that helps antibodies and phagocytic cells destroy pathogens. It is activated via three pathways - classical, lectin, and alternative. Activation leads to a cascade of reactions that results in the formation of the membrane attack complex, which punches holes in the pathogen's cell membrane, killing it. Complement also aids in inflammation, phagocytosis, and immune adherence. The system is tightly regulated to prevent damage to host cells. Deficiencies can cause diseases like hereditary angioedema.
Describes the complement system components and their activation pathways, the regulation of the complement
system, the effector functions of various complement components,
and the consequences of deficiencies in them.
This document discusses inflammation and its triggers, objectives, and results. It describes the cardinal signs of inflammation as redness, swelling, heat, pain, and loss of function. It differentiates between acute and chronic inflammation and discusses the cells, mediators, and systemic effects involved in each. Key aspects of the inflammatory response like increased vascular permeability, leukocyte recruitment, recognition of pathogens, and termination signals are explained.
El documento resume las características del angioedema, incluyendo sus manifestaciones clínicas, tipos, causas, fisiopatología, diagnóstico y tratamiento. Describe el angioedema como un edema de la piel y tejido subcutáneo, que puede ser alérgico, hereditario o inducido por fármacos. Explica que se debe a una aumento de la permeabilidad vascular causado por mediadores como la histamina y la bradicinina.
This document provides information on acute rheumatic fever (ARF), including its definition, incidence, pathophysiology, diagnosis, management, and secondary prevention. ARF is an autoimmune response to Group A streptococcal infection that causes inflammation of the heart, joints, brain and skin. It predominantly affects school-aged children and those in low socioeconomic conditions. Accurate diagnosis is important to avoid over- or under-treatment. Management involves treating streptococcal infections, suppressing inflammation, and long-term antibiotic prophylaxis to prevent recurrence.
Management of hereditary angioedema involves treating acute attacks, preventing attacks, and improving quality of life. Treatment strategies include treating acute attacks, preventing attacks short-term before procedures, and long-term prophylaxis. Therapies include C1 inhibitor replacement, bradykinin receptor antagonists, attenuated androgens, and antifibrinolytics. An individualized treatment plan is recommended based on a patient's attack frequency, severity and location, as well as their medication access and preferences.
This document summarizes information on chronic urticaria, including its prevalence, causes, impact on quality of life, and treatment options. It notes that chronic urticaria affects approximately 1% of people with acute urticaria and has a significant negative impact on quality of life. First-line treatment includes non-sedating antihistamines, sometimes at higher off-label doses. If patients do not respond sufficiently to antihistamines alone, second-line options include doxepin, leukotriene antagonists, short-term corticosteroids, dapsone, sulfasalazine, and narrowband UVB phototherapy. The document reviews evidence on the efficacy and safety of these second-
Onali S. IBD: Cosa è cambiato nella Terapia. ASMaD 2013Gianfranco Tammaro
1. The document discusses inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. It covers epidemiology, pathophysiology, clinical presentation, goals of treatment, and current treatment options.
2. Key points include that immunosuppressors like azathioprine and 6-mercaptopurine are effective for long-term maintenance of remission, while biologics like infliximab are rapidly effective but their use is expanding.
3. Achieving mucosal healing is an important new treatment goal, especially in ulcerative colitis, as it predicts sustained clinical remission. Management must be tailored to each individual patient based on their disease characteristics and needs.
This study investigated the effects of hydrocortisone therapy on patients with septic shock. It found no significant difference in 28-day mortality between patients given hydrocortisone and those given placebo. While hydrocortisone hastened the reversal of shock, it also increased risks of superinfection and hyperglycemia. Based on these results, hydrocortisone cannot be recommended as general therapy for septic shock patients.
This presentation deals with the in-depth analysis of various cardiac stimulants & depressants both directly & indirectly acting on frog's heart. Also, includes a nice quiz, a good exercise for the grey cells of the brain at the end of the presentation.
This document summarizes recent advances in the treatment of pulmonary arterial hypertension (PAH). It discusses new drugs such as macitentan and riociguat that have been shown to improve outcomes in clinical trials. It also describes an experimental treatment called pulmonary artery denervation that aims to reduce pulmonary artery pressure by ablating nerve endings around the pulmonary arteries. The document reviews the clinical evidence from trials of these new treatments and identifies limitations and areas needing further study to improve outcomes for patients with PAH.
This document provides information on acute radiation syndrome (ARS), including its clinical presentation, diagnosis, and treatment. It describes the various syndromes (hematopoietic, gastrointestinal, neurovascular) that can occur depending on radiation dose. It discusses factors that influence severity and outlines medical management approaches like isolation, infection prevention, total parenteral nutrition, cytokine therapy, and conventional therapy for thrombocytopenia. The goal of treatment is to reduce the depth and duration of symptoms like leukopenia and allow hematopoietic recovery.
The document discusses the role of corticosteroids in treating allergic diseases, describing how corticosteroids work to reduce inflammation and summarizing their use in treating conditions like asthma, allergic rhinitis, atopic dermatitis, and anaphylaxis. Guidelines are provided on the appropriate use of corticosteroids for different severity levels of allergic diseases both orally and through inhalation.
An elderly woman with multiple comorbidities suffered from COVID 19 moderate disease - was managed conservatively
Case presentation with current treatment modalities
This document provides an overview of sepsis and septic shock. It defines the clinical syndromes related to sepsis including systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock. It outlines the goals of treating septic shock which include initial fluid resuscitation, stabilizing hemodynamics with pressors, administering antibiotics, and interrupting inflammatory mediators. It discusses early goal directed therapy for septic shock patients, which aims to achieve specific goals regarding central venous pressure, mean arterial pressure, and central venous oxygen saturation within the first 6 hours in order to decrease mortality.
Intensive Insulin Therapy In The Medical IcuNadSamm
Intensive insulin therapy (IIT) aimed at maintaining tight glycemic control between 4.4-6.1 mmol/L significantly reduced morbidity but not overall in-hospital mortality compared to conventional insulin treatment targeting levels below 10-12 mmol/L in critically ill adult medical ICU patients. Among patients who received at least 3 days of IIT, in-hospital mortality was reduced from 21% to 14% and complications such as newly acquired kidney injury and length of stay were also lower. However, IIT did not reduce mortality in the overall intention-to-treat analysis and may have caused harm in patients treated for less than 3 days. Further research is needed to confirm these preliminary findings.
This document provides guidelines for the management of sepsis and septic shock. It outlines criteria for diagnosing sepsis, severe sepsis, and septic shock. It recommends initial resuscitation efforts within 3 hours that include measuring lactate, obtaining blood cultures, administering antibiotics and fluids. The guidelines recommend targeting a mean arterial pressure of 65 mmHg with vasopressors as needed, and normalizing lactate if initially elevated. Source control through drainage or removal of infection sites is also advised within 12 hours of diagnosis if possible.
Acquired hemophilia A is a rare bleeding disorder caused by autoantibodies against factor VIII. It most commonly presents in older patients as severe bleeding and has a high mortality rate if not properly treated. Evaluation involves testing for prolonged aPTT and ruling out an inhibitor through mixing studies. Treatment focuses on controlling bleeding with bypassing agents or factor VIII while also using immunosuppressants to eliminate the autoantibody inhibitor. Proper management can reduce bleeding and inhibitor levels, but monitoring is needed due to the slow response to therapy.
Hemophagocytic Lymphohistiocytosis (HLH) is an aggressive and life threatening syndrome which results from excessive immune activation, that can rapidly deteriorate and lead to multiple organ failure and death.
This document summarizes guidelines from the Surviving Sepsis Campaign for the management of severe sepsis and septic shock. It provides an update to previous guidelines published in 2004. The guidelines were created by an international panel of experts using the GRADE system to assess evidence quality and determine recommendation strength. Key recommendations include early goal-directed resuscitation, appropriate antibiotic therapy, source control, fluid resuscitation, vasopressor use, steroid therapy, lung-protective ventilation, glycemic control, renal replacement therapy, thrombosis prophylaxis, and stress ulcer prophylaxis. The guidelines are intended to improve outcomes for patients with severe sepsis or septic shock.
A 63-year-old Caucasian woman presented with depressive syndrome and elevated liver enzymes but no extrahepatic manifestations. Liver biopsy showed cirrhosis with moderate activity and pericentral necrosis. She was treated with prednisone and azathioprine, achieving remission within 3 months. Azathioprine was stopped after 2 years due to normal liver enzymes and decreased IgG levels. Her case illustrates treatment and monitoring of autoimmune hepatitis.
- Cat and dog allergens such as Fel d 1 and Can f 1 are major allergens found in fur, dander, and saliva that can become airborne and cause sensitization in a large percentage of allergic individuals.
- Lipocalins make up many mammalian allergens and show cross-reactivity between species due to structural similarities, explaining co-sensitizations between cats, dogs, horses, and other animals.
- Higher levels of IgE antibodies to specific dog lipocalins are associated with more severe asthma in children with dog allergy.
1) DRESS syndrome is a severe cutaneous drug reaction characterized by fever, lymphadenopathy, hematologic abnormalities, multisystem involvement, and viral reactivation. It has a delayed onset of 2-3 weeks after starting the culprit drug.
2) The skin manifestations are typically a polymorphous maculopapular eruption and facial edema. Systemic involvement can include the liver, kidneys, lungs and other organs.
3) Diagnosis is based on clinical criteria including the RegiSCAR scoring system which evaluates morphology, timing of onset, organ involvement, hematologic abnormalities and viral reactivation.
Wheat is one of the most important global food sources and wheat allergy prevalence varies from 0.4-4% depending on age and region. Several wheat proteins have been identified as major allergens, including omega-5-gliadin, alpha-amylase inhibitors, and glutenins. Studies have found that serum testing for IgE antibodies to specific wheat allergens, such as omega-5-gliadin, glutenins, and alpha-amylase inhibitors, can help diagnose wheat allergy and distinguish between mild and severe cases. Sensitization to different wheat allergens is associated with wheat-dependent exercise-induced anaphylaxis versus occupational baker's asthma. Proper diagnosis and
Major indoor allergens include dust mites, domestic animals like cats and dogs, insects like cockroaches, mice, and fungi. Dust mites thrive in warm, humid environments like mattresses, bedding, and upholstered furniture, where they feed on human skin scales and excrete allergenic fecal particles. Cat allergens like Fel d 1 accumulate in fur and can become airborne, causing worse asthma outcomes in sensitized individuals. Minimizing exposure involves removing carpets, frequent washing of bedding, humidity control, HEPA filtration and ventilation.
This document provides information on Hymenoptera, focusing on the families Apidae and Vespidae. It discusses the epidemiology and prevalence of insect venom allergy. It also covers the taxonomy, venom composition, and clinical manifestations of common stinging insects like honeybees, hornets, wasps and yellow jackets. Key allergens are identified for different species.
- NSAIDs hypersensitivity can present with distinct clinical phenotypes based on organ system involvement and timing of symptoms. It is estimated that less than 20% of reported adverse reactions to NSAIDs are true hypersensitivities.
- AERD/NERD involves eosinophilic rhinosinusitis, asthma, and nasal polyps. Exposure to aspirin or other NSAIDs exacerbates bronchospasms and rhinitis. Management involves lifelong avoidance of culprit and cross-reacting NSAIDs.
- Various phenotypes are described beyond the EAACI classification, including blended reactions involving multiple organs, food-dependent NSAID-induced anaphylaxis, and NSAID-selective immediate reactions. Proper diagnosis relies
The document discusses food immunotherapy for treating food allergies. It provides definitions and outlines immune mechanisms and efficacy evidence from studies on peanut, cow's milk, egg, and wheat oral immunotherapy (OIT). Peanut OIT studies showed 67-78% of children achieved desensitization and 21-46% achieved sustained unresponsiveness. Cow's milk and egg OIT also demonstrated desensitization in 50-75% of children. Wheat OIT studies found 52-69% achieved desensitization. OIT was effective at increasing tolerance but also increased rates of adverse events during treatment.
This document summarizes X-linked agammaglobulinemia (XLA), an inherited primary immunodeficiency caused by mutations in the Bruton's tyrosine kinase (Btk) gene. XLA is characterized by absent B cells and low immunoglobulin levels, leading to recurrent bacterial infections starting in infancy. Management involves immunoglobulin replacement and antibiotic therapy. With treatment, life expectancy has improved dramatically though complications can include lung disease. The document also briefly discusses other forms of agammaglobulinemia caused by defects in genes important for early B cell development.
This document discusses histamine and anti-histamines. It provides information on:
1. The structure and function of histamine and its receptors in immune response regulation. Histamine plays a role in processes like antigen presentation and influencing T and B cell responses.
2. The classification and structures of different types of anti-histamines, including first and second generation anti-histamines from different chemical classes.
3. Some anti-histamines have the potential to cause hypersensitivity in rare cases, even those from different chemical classes with no structural similarity.
The document discusses beta-lactam allergy, including penicillin and cephalosporin allergies. It covers the epidemiology, classifications, structures, mechanisms, and investigations of beta-lactam allergies. Specifically, it notes that penicillin is the most commonly reported antibiotic allergy. It describes the hapten concept of small molecules like beta-lactams binding covalently to proteins to form antigen complexes. Skin testing and in vitro tests are used to investigate immediate IgE-mediated allergies, while patch testing is used for delayed reactions.
This document provides an overview of intravenous immunoglobulin (IVIG) therapy. It discusses the structure and classes of immunoglobulins, mechanisms of action including neutralization, opsonization, and modulation of immune cells. It also covers the manufacturing process, pharmacokinetics, indications for use in primary immunodeficiencies and autoimmune diseases, dosing, administration, and adverse effects. The differences between IVIG products are also reviewed.
More from Chulalongkorn Allergy and Clinical Immunology Research Group (20)
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Co-Chairs, Val J. Lowe, MD, and Cyrus A. Raji, MD, PhD, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/AAPA activity titled “Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neuroradiology in Diagnosis and Treatment.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/3PvVY25. CME/AAPA credit will be available until June 28, 2025.
low birth weight presentation. Low birth weight (LBW) infant is defined as the one whose birth weight is less than 2500g irrespective of their gestational age. Premature birth and low birth weight(LBW) is still a serious problem in newborn. Causing high morbidity and mortality rate worldwide. The nursing care provide to low birth weight babies is crucial in promoting their overall health and development. Through careful assessment, diagnosis,, planning, and evaluation plays a vital role in ensuring these vulnerable infants receive the specialize care they need. In India every third of the infant weight less than 2500g.
Birth period, socioeconomical status, nutritional and intrauterine environment are the factors influencing low birth weight
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
How to Control Your Asthma Tips by gokuldas hospital.Gokuldas Hospital
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
2. Outline Introduction HAE treatment: past present and future 2010 International consensus
3. Introduction Hereditary angioedema autosomal-dominant disorder abnormality in levels or functionality of C1INH Mutations (> 200) located on chromosome 11 20- 25% of cases result from new spontaneous mutation Prevalence : 1 in 50,000 Type 1 HAE (80- 85%) reduced circulating C1INH concentrations ( levels ~ 5- 30% of expected values) mutations occur throughout the gene type 2 HAE (15- 20%) dysfunctional protein , single amino acid substitutions mutations J Allergy ClinImmunol2010;126:918-25.
4. Introduction Hereditary angioedema Type 3 HAE predominantly in female subjects not related to C1INH deficiency missense mutation in factor XII gene7 (subpopulation) Excessive bradykinin formation predisposing factor apart from estrogen or trauma Attacks in untreated patients can last 2-5 days history of recurrent attacks of peripheral angioedema (nonpruritic, nonpitting) and/or abdominal pain in absence of urticaria Swelling most commonly extremities, face, or genitalia J Allergy ClinImmunol2010;126:918-25.
14. Kallikrein thus formed (dotted lines) caninitiate factor XII-dependent activation at adjacent cellsJ Allergy ClinImmunol2010;126:918-25
15. Dysregulation of Complement, Coagulation, and Contact Cascades in Hereditary Angioedema C1 inhibitor controls activation in complement, coagulation, and contact cascades, and all three cascades are dysregulated in HAE N Engl J Med 363;6 Nejm.Org August 5, 2010
16. HAE treatment: The past Treatment of acute HAE attacks Until late 2008, no drug approved in US symptomatic control of swelling Aggressive IV replacement, control of pain and nausea with parenteralnarcotic and antiemetic drugs ( abdominal attack ) Intubate or emergency tracheotomy ( airway attack ) Not require treatment (angioedemaof extremities ) Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
17. HAE treatment: The past Long-term prophylaxis Goal : decrease frequency and/or severity of swelling attacks attack every 3 months location of attacks (airway attacks ) Accessibility to appropriate medical care Avoid ACEI, Birth control pills and HRT Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
18. HAE treatment: The past Long-term prophylaxis anabolic androgens increase C1INH plasma levels and decrease attacks of HAE Danazol and stanozolol (synthetic 17-a-alkylated androgens ) 2 mg stanozolol OD or AD or 200 mg danazol OD or AD precise mechanism be elucidated side effects (dose related) : hepatotoxicity , hepatic adenoma and virulization Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
19. HAE treatment: The past Long-term prophylaxis anti-fibrinolytics epsilon aminocaproicacid (EACA or Amicar) and tranexamicacid Less effective than anabolic hormone reserved for not tolerate anabolic androgens ( children and pregnant women ) Tranexamicacid not currently available in US EACA : 1 gm orally 3-4 times per day Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
20. HAE treatment: The past Short-term prophylaxis All HAE patients need for short-term prophylaxis Prevent attacks before expected trauma eg. surgery or dental procedures avoid potentially catastrophic swelling High-dose anabolic androgen therapy (stanozolol 2 mg three times daily or danazol 200 mg three times daily) begun 5 to 7 days before procedure 2 units of FFP several hours before procedure Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
21. HAE treatment: The present Over the past 18 months, 3 new medications for treatment of HAE approved in US Plasma-derived C1INH concentrates Pasteurized plasma-derived C1INH concentrate Nanofiltered and pasteurized plasma-derived C1INH concentrate Plasma kallikrein inhibitor: Ecallantide
22. Pasteurized plasma-derived C1INH concentrate Berinert (CSL Behring) : pasteurized lyophilized human plasma-derived C1 inhibitor concentrate licensed in Europe over 20 years (acute, short term) phase III study for acute attacks ( IMPACT1) Compared efficacy (shortening onset of relief of symptoms) Berinert (10 U/kg and 20 U/kg) to placebo in 125 HAE patients with moderate to severe abdominal or facial angioedema attacks primary outcome : time from start of treatment to onset of symptom relief Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
25. Berinertreceived approval from FDA (2009) for use in treatment of acute angioedema attacks in adolescent and adult HAE patients Pasteurized plasma-derived C1INH concentrate Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
26. Nanofiltered and pasteurized plasma-derived C1INH concentrate Cinryze (ViroPharmaIncorporated) nanofiltered pasteurized lyophilized C1INH concentrate Manufactured in Netherlands, using U.S. plasma final nanofiltration step, provides additional protection against enveloped and non-enveloped viral particles and possibly prions Two separate randomized double-blind placebo controlled studies of Cinryze performed in US Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
27. Nanofiltered C1 Inhibitor Concentrate for Treatment of acute HAE CHANGE part A efficacy and safety of C1INHnf for treatment of moderate to severe acute attacks of facial, abdominal or genitourinary angioedemain HAE patients infused with C1INH-nf 1,000 IU (35pt.) or placebo (33pt.) at time 0 If significant relief not reported within 60 minutes, given second dose of same study drug All subjects eligible to receive open-label Cinryze after 4 hours N Engl J Med 363;6 Nejm.Org August 5, 2010
28. Nanofiltered and pasteurized plasma-derived C1INH concentrate primary end point : time to onset of unequivocal relief of symptom at defining sites median time to onset of unequivocal relief from attack =2 hours ( C1 INHnf ) but > 4 hours in placebo (P = 0.02) median time to complete resolution of symptoms was 12.3 hours (C1 inh group) and 25.0 hours ( placebo group) (P = 0.004)
29. Nanofiltered C1 Inhibitor Concentrate for Treatment of acute HAE Primary Outcome in the Trial of C1 Inhibitor Therapy for Acute Attacks of Angioedema Cumulative incidence estimates for time to onset of unequivocal relief (primary outcome) 35 subjects received C1 INHnfand 33 subjects received placebo circles represent subjects who received rescue therapy before 4 hours ( 2 subjects in placebo group received narcotic rescue at 15 and 146 minutes, respectively, and 1 subject in C1 INH group received open-label C1 INH rescue at 110 minutes) or those who not have onset of unequivocal relief before 4 hours (60%) (P=0.06) (42%) N Engl J Med 363;6 Nejm.Org August 5, 2010
30. Nanofiltered C1 Inhibitor Concentrate for prophylaxis of HAE CHANGE part B Longterm prophylaxis to prevent attacks of angioedema RDBPC crossover trial involving 22 subjects with hereditary angioedema that compared prophylactic twice-weekly injections of C1 INHnf (1000 units) with placebo during two 12-week periods primary end point : number of attacks of angioedema per period During C1INH-nf treatment periods, showed highly significant decrease in HAE attacks (6.26 versus 12.73 attacks; p < 0.0001) N Engl J Med 363;6 Nejm.Org August 5, 2010
31. Nanofiltered C1 Inhibitor Concentrate for Treatment of acute HAE attack rates are shown for each of 22 subjects during 12-week period when either placebo or C1 INHnf black horizontal lines indicate mean attack rates for two treatments, 6.3 and 12.7 for C1 inhibitor group and placebo group, respectively Normalized Rate of Angioedema Attacks During Prophylaxis Trial N Engl J Med 363;6 Nejm.Org August 5, 2010
32. Nanofiltered C1 Inhibitor Concentrate for Treatment of acute HAE Adverse events In C1 INH group Possibly : fever (1),lightheadedness (1) Definitely : rash at injection site (1), pruritus and rash (1) In placebo group Possibly : carpopedal spasm (1), erythema (1) Definitely : contact dermatitis (1), chest discomfort (1), cough (1) N Engl J Med 363;6 Nejm.Org August 5, 2010
33.
34. The application for use of Cinryze to treat acute attacks of angioedemais still pendingNanofiltered and pasteurized plasma-derived C1INH concentrate Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
35. Plasma kallikrein inhibitor: Ecallantide( Kalbitor ) novel, potent and specific plasma kallikreininhibitor recombinant, 60-amino acid protein produced in Pichiapastoris yeast recommended dose to treat angioedemaattack is 30 mg, administered as three 1 ml sc injections Maximum ecallantidelevels reached 2-3 hours following subcutaneous injection, HL~ 2 hours 2 separate RDBPC phase III studies of ecallantide for Rx of acute attacks of HAE performed in US EDEMA 3 EDEMA 4 N Engl J Med 363;6 Nejm.Org August 5, 2010
36. Ecallantide for the Treatment of Acute Attacks in HAE (EDEMA3) RDBPC trial, acute attack , 1:1 ratio, to receive sc ecallantide (30 mg) or placebo 72 patients Primary endpoint : treatment outcome score (TOS) at 4 hours TOS : patient-reported measure of response to therapy using categorical scale from 100 (significant improvement) to -100 (significant worsening) for each symptom complex, weighted according to its baseline severity N Engl J Med 363;6 Nejm.Org August 5, 2010
37. Ecallantide for the Treatment of Acute Attacks in HAE Efficacy Analyses with Respect to Primary and Secondary End Points, According to Study Group. N Engl J Med 363;6 Nejm.Org August 5, 2010
38. Ecallantide for the Treatment of Acute Attacks in HAE Efficacy Analyses with Respect to Primary and Secondary End Points, According to Study Group. N Engl J Med 363;6 Nejm.Org August 5, 2010
39. Ecallantide for the Treatment of Acute Attacks in HAE Kaplan–Meier Analysis of Time to Significant Improvement in Overall Response in the Intention-to-Treat Population. N Engl J Med 363;6 Nejm.Org August 5, 2010
40. Ecallantide for the Treatment of Acute Attacks in HAE Adverse Events in the Safety Population, According to Study Group N Engl J Med 363;6 Nejm.Org August 5, 2010
41. Ecallantide for the Treatment of Acute Attacks in HAE (EDEMA4) 96 patients primary endpoint : mean symptom complex severity (MSCS) at 4 hours MSCS score : patient-reported point-in-time measure of symptom severity based on symptom rating of 0 (none) to 3 (severe) for each potential symptom complex Mean decrease in symptom score at 4 hours of 0.81 (Ecallantide ) compared to 0.37 in placebo (p = 0.01) Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
42. Plasma kallikrein inhibitor: Ecallantide Prolongation of aPTT (common), without any enhanced risk of bleeding Anaphylactic-like reactions in 10/255 (3.9%) subjects following exposure to ecallantide Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
43.
44. black box warning on anaphylactic potential and requiring that the drug be administered by health care providerPlasma kallikrein inhibitor: Ecallantide Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
45. HAE treatment: The future Recombinant human C1INH Icatibant Other future directions Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
46. Recombinant human C1INH J Allergy ClinImmunol 2010;126:821-7. Rhucin (Pharming NV) recombinant human C1 inhibitor (rhC1INH) concentrate for iv infusion isolated from milk of transgenic rabbits identical to human plasma derived C1INH at amino acid level 2separate phase III studies ,for rhC1INH in treatment of acute attacks of angioedemain HAE patients
47. Recombinant human C1INH European RDBPC rhC1INH (100 U/kg) in 32 HAE patients was stopped on ethical grounds because of strong and highly significant positive advantage for rhC1INH versus placebo in median time to beginning of relief (62 versus 508 minutes, p = 0.0009) as well as time to minimal symptoms (480 versus 1480 minutes, p = 0.0038) Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
48. Recombinant human C1INH In US and Canada 39 subjects showed significant benefit for rhC1INH versus placebo in median time to beginning of relief (68 minutes for rhC1INH 100 U/kg, 122 minutes for rhC1INH 50 U/kg, and 258 minutes for placebo) Time to minimal symptoms significantly shortened after treatment with rhC1INH (245 minutes at 100 U/kg and 247 minutes at 50 U/kg) compared to placebo (1101 minutes) (P<0.01) Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
49. Recombinant human C1-inhibitor for treatment of acute angioedema attacks Primary and secondary efficacy outcome in 3 treatment groups J Allergy ClinImmunol 2010;126:821-7.
50. Recombinant human C1-inhibitor for treatment of acute angioedema attacks Course of mean VAS scores in time in rhC1INH and saline groups Data indicate mean VAS scores and 95% CIs. J Allergy ClinImmunol 2010;126:821-7.
51. Recombinant human C1-inhibitor for treatment of acute angioedema attacks Adverse events In C1 INH Headache, vertigo colitis In placebo Headache, injection site swelling, epistaxis, hypotension J Allergy ClinImmunol 2010;126:821-7.
52. Icatibant, New Bradykinin-Receptor Antagonist, in HAE Icatibant (Firazyr, Shire) synthetic selective decapeptidebradykinin B2 receptor competitive antagonist contains 5 non-natural amino acids to enhance resistance to peptidases Icatibant administered sc injection as single 30 mg peak concentration within 30 minutes, and HL~ 1-2 hours 2 RDBPC phase III study : FAST-1(US) ,FAST-2 (Europe) N Engl J Med 363;6 Nejm.Org August 5, 2010
53. Icatibant, New Bradykinin-Receptor Antagonist, in HAE 56 subjects (FAST-1) 72 subjects (FAST-2) moderate to severe abdominal or cutaneousangioedemaattack Primary endpoint time to onset of symptom relief assessed by subject recorded visual analog scale (VAS) Secondary endpoints time to almost complete symptom relief and response rate at 4 hours Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
55. Icatibant, New Bradykinin-Receptor Antagonist, in HAE Adverse Events in the Safety Populations of the FAST-1 and FAST-2 Trials. N Engl J Med 363;6 Nejm.Org August 5, 2010
56.
57. The FDA disapproved the application for licensure,And new RDBPC phase III trial (FAST3) is ongoingIcatibant, New Bradykinin-Receptor Antagonist, in HAE N Engl J Med 363;6 Nejm.Org August 5, 2010
58. Other future directions administering C1INH concentrate by sub-cutaneous infusion steady plasma levels of C1INH during longterm prophylaxis inhibition of factor XII activity might prevent bradykiningeneration Like strategies targeting plasma kallikrein orally available bradykininreceptor antagonists combined bradykinin B2 and B1 receptor antagonism recent demonstration that B1 receptor may play role in swelling of HAE patients gene repair or intracellular trafficking for molecular correction of defects in HAE N Engl J Med 363;6 Nejm.Org August 5, 2010
59. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema Bowen et al. Allergy, Asthma & Clinical Immunology 2010, 6:24